GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (NSE:SPARC) » Definitions » 3-Year FCF Growth Rate

Sun Pharma Advanced Research Co (NSE:SPARC) 3-Year FCF Growth Rate : -32.60% (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co 3-Year FCF Growth Rate?

Sun Pharma Advanced Research Co's Free Cash Flow per Share for the three months ended in Sep. 2024 was ₹0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -32.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Sun Pharma Advanced Research Co was 53.90% per year. The lowest was -355.20% per year. And the median was -8.20% per year.


Competitive Comparison of Sun Pharma Advanced Research Co's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's 3-Year FCF Growth Rate falls into.



Sun Pharma Advanced Research Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Sun Pharma Advanced Research Co  (NSE:SPARC) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Sun Pharma Advanced Research Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Sun Pharma Advanced Research Co Business Description

Traded in Other Exchanges
Address
Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in othe4r countries.

Sun Pharma Advanced Research Co Headlines

No Headlines